Hydroxybupropion is the primary active metabolite of bupropion, the medication sold under brand names like Wellbutrin and Zyban. When you take bupropion, your liver converts it into hydroxybupropion, and this breakdown product actually reaches blood concentrations 4 to 5 times higher than the original drug. Far from being a waste product, hydroxybupropion is now understood to be a major driver of bupropion’s antidepressant and smoking cessation effects.
How Your Body Creates Hydroxybupropion
After you swallow a bupropion tablet, a liver enzyme called CYP2B6 converts it into hydroxybupropion. This is the dominant metabolic pathway, though two other minor enzymes can contribute at higher doses. Your liver also produces two other active metabolites (threohydrobupropion and erythrohydrobupropion) through a different enzymatic route, but hydroxybupropion is the one that has received the most clinical attention.
The conversion happens quickly and extensively. At steady state, hydroxybupropion’s area under the curve (a measure of total drug exposure over time) is roughly 17 times that of bupropion itself. Its elimination half-life is about 20 hours, considerably longer than bupropion’s, which means it lingers in your system and accumulates to high levels with regular dosing. In practical terms, hydroxybupropion is the compound doing most of the work in your bloodstream while you’re on bupropion.
What Hydroxybupropion Does in the Brain
Bupropion is classified as a norepinephrine-dopamine reuptake inhibitor, meaning it increases the availability of two key brain chemicals involved in mood, motivation, and reward. Hydroxybupropion acts on the same systems. It binds to the norepinephrine transporter with nearly the same strength as bupropion itself and has roughly 50% of bupropion’s antidepressant activity in lab models. That might sound weaker, but remember: hydroxybupropion circulates at concentrations about 10 times higher than the parent drug during treatment. Those much higher blood levels more than compensate for any reduced potency at individual receptors, producing meaningful effects on both norepinephrine and dopamine signaling at normal therapeutic doses.
The combined action of bupropion and hydroxybupropion together is thought to be what reduces nicotine reward and eases withdrawal symptoms. Clinical data backs this up: people who metabolize bupropion into hydroxybupropion more efficiently, producing higher blood levels of the metabolite, tend to have better quit rates when using bupropion for smoking cessation. This finding has led researchers to conclude that hydroxybupropion, not bupropion itself, may be the primary reason the drug helps people stop smoking.
Why Genetics Affect Your Response
Not everyone converts bupropion to hydroxybupropion at the same rate. The CYP2B6 enzyme that handles this conversion varies significantly from person to person based on genetics. Two well-studied gene variants, known as CYP2B6*6 and CYP2B6*18, reduce hydroxybupropion concentrations by approximately 33%. People carrying these variants produce less functional enzyme, which means less of the active metabolite reaches their bloodstream.
Sex also plays a role. Women tend to produce higher levels of hydroxybupropion than men at the same dose, though the ratio of metabolite to parent drug is similar between the sexes, suggesting this reflects differences in overall drug processing rather than enzyme activity specifically. Even accounting for genetics and sex, researchers can only explain about 50% of the variation in hydroxybupropion levels between individuals. The rest comes from untested genetic variants, other medications, and individual differences in liver function.
Drug Interactions That Shift Metabolite Levels
Because hydroxybupropion formation depends almost entirely on one enzyme, anything that blocks or boosts CYP2B6 activity can meaningfully change how much of the metabolite you produce. Selegiline, a medication used for Parkinson’s disease and sometimes depression, is a strong inhibitor of this pathway. In laboratory studies, it dramatically reduced the enzyme’s ability to process bupropion, raising the possibility of significant interactions when the two drugs are used together.
On the other side, certain medications can ramp up CYP2B6 activity. Drugs like rifampin (an antibiotic), phenytoin, and carbamazepine (both anti-seizure medications) are known inducers of this enzyme family. If you’re taking one of these alongside bupropion, your body may convert bupropion to hydroxybupropion faster than expected, altering the balance between parent drug and metabolite.
Its Role in Depression and Smoking Cessation
For years, the clinical importance of hydroxybupropion was underappreciated. Bupropion got the credit, while hydroxybupropion was treated as just a metabolic byproduct. That picture has shifted substantially. Hydroxybupropion is now considered critical to bupropion’s antidepressant effects, particularly through its actions on norepinephrine and dopamine systems.
The evidence is strongest for smoking cessation. Studies have shown a direct relationship between hydroxybupropion plasma levels and quit success: higher levels of the metabolite correlate with better outcomes. This has made hydroxybupropion a focus for future drug development, with researchers describing it as the most promising starting point for designing next-generation smoking cessation treatments. Some scientists argue that when you take bupropion to quit smoking, you’re essentially taking a prodrug, a substance whose real therapeutic value comes from what your body turns it into.
Why It Shows Up on Lab Tests
If you’ve encountered the term hydroxybupropion on a drug test or lab report, there’s a straightforward explanation. Because hydroxybupropion is present at much higher concentrations than bupropion and lasts longer in the body, drug monitoring panels sometimes measure it directly. Its 20-hour half-life means it takes several days after stopping bupropion for hydroxybupropion to fully clear your system. In urine drug screening, bupropion and its metabolites have occasionally been flagged as false positives for amphetamines on immunoassay tests, though confirmatory testing can distinguish between the two.